Nexstim NBT® system authorized for commercial distribution in Australia
Helsinki, Finland: 5 August 2019 – Nexstim Plc (NXTMH:HEX, NXTMS:STO) – the targeted neuromodulation company developing and marketing pioneering navigated personalised, non-invasive brain stimulation systems for the treatment of major depressive disorder (MDD) – announces that its NBT® system has received a medical device licence from the Health Department of Australian Government.
The medical device licence allows Nexstim to start marketing and selling the NBT® system for the treatment of major depressive disorder (MDD) in Australia.
The NBT® system uses a unique technology of nTMS known as SmartFocus® which allows for accurate, reproducible stimulation of the specific area of the brain associated with the treatment of depression.
Further information is available on Nexstim’s website.